JPRN-UMIN000031867
Completed
未知
The Effect of SGLT2 inhibitor Tofogliflozin to Quality of Life of Patients with Type 2 Diabetes Mellitus Research - The Effect of SGLT2 inhibitor Tofogliflozin to Quality of Life of Patients with Type 2 Diabetes Mellitus Research (SGITR study)
HO Kyoto Medical Center, Diabetes Center0 sites30 target enrollmentMarch 26, 2018
ConditionsType 2 diabetes mellitus
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 diabetes mellitus
- Sponsor
- HO Kyoto Medical Center, Diabetes Center
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients using pharmaceuticals to treat diabetes mellitus other than DPP\-4 inhibitor and sulfonyl urea and insulin (including GLP\-1 receptor agonist) for 3 month or more prior to the moment starting tofogliflozin. 2\) Patients with the serum creatinine levels of 2\.0 mg/dl or more. 3\) Patients with hypothyroidism. 4\) Patients with hyperthyroidism. 5\) Patients with BMI less than 18\.5 kg/m2, or 40 kg/m2 or more. 6\) Patients who have allergy to tofogliflozin. 7\) Patients with severe ketosiss, diabetic coma or impending diabetic coma. 8\) Patinets with severe infection, in perioperative period, or with severe trauma. 9\) Patients to whom participating this study is considered to be inappropriate for any reason.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.JPRN-UMIN000025454Dokkyo Medical University Department of Endocrinology and Metabolism20
Completed
Phase 2
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesDiabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424NL-OMON48616Radboud Universitair Medisch Centrum15
Active, not recruiting
Phase 1
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2018-001569-17-NLRadboud university medical center15
Completed
Not Applicable
Effects of tofogliflozin treatment on suppression of nocturia and promotion of urinary sodium excretion.JPRN-UMIN000048030Department of Metabolism and Endocrinology, Akita University Graduate School of Medicine36
Completed
Not Applicable
Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particlesType 2 diabetesJPRN-UMIN000020027Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy30